FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281629140> ?p ?o ?g. }

• W4281629140 endingPage "TPS7588" @default.
• W4281629140 startingPage "TPS7588" @default.
• W4281629140 abstract "TPS7588 Background: Despite significant progress with first-line immunochemotherapy, most patients with follicular lymphoma (FL) will eventually relapse with increasing refractoriness and decreasing duration of response to subsequent therapy lines (Rivas-Delgado et al. 2019). Mosunetuzumab (M) is a CD20xCD3 bispecific antibody that engages and redirects T-cells to eliminate malignant B cells (Sun et al. 2015). In an ongoing, pivotal Phase I/II trial of M monotherapy, patients with relapsed/refractory (R/R) FL who have received ≥2 prior treatment lines achieve deep and durable responses (NCT02500407; Budde et al. ASH 2021). Preliminary data from a Phase Ib study have suggested favorable safety and promising activity of M in combination with lenalidomide (Len), a potent immunomodulatory agent that has shown additive/synergistic activity with an anti-CD20 antibody in R/R indolent lymphoma (Leonard et al. 2019), in patients with R/R FL who have received ≥1 prior therapy (NCT04246086; Morschhauser et al. ASH 2021). The chemotherapy-free M-Len combination may represent a promising outpatient therapy option for future management of patients with R/R FL. The randomized, multicenter Phase III study has been initiated. Methods: CELESTIMO (NCT04712097) is a randomized, multicenter, open-label Phase III study evaluating the efficacy and safety of M-Len versus rituximab plus Len (R-Len) in patients with previously treated R/R FL. Patients must have histologically documented CD20+ FL (Grades 1–3a) requiring systemic therapy and have received ≥1 prior line of systemic therapy. Patients are randomized (1:1) to receive M-Len (M intravenously [IV] on Days [D] 1, 8 and 15 of Cycle [C] 1 [21-day cycle] and D1 of C2–12 [28-day cycles], plus Len orally [PO] on D1–21 of C2–12) or R-Len (R IV on D1, 8, 15 and 22 of C1 then on D1 of C3, 5, 7, 9, and 11, plus Len PO on D1–21 of C1–12 [all 28-day cycles]), and stratified by disease progression within 24 months of initial treatment (yes/no), number of prior lines of therapy (1 versus ≥2), and refractoriness to anti-CD20 therapy (refractory/non-refractory). The primary endpoint is progression-free survival (PFS) assessed by independent review committee; secondary endpoints include investigator-assessed PFS, complete and objective response, overall survival, and safety. Biomarkers predictive of response to M-Len and R-Len will also be investigated as exploratory endpoints. The study started recruitment in 2021 and plans to enroll ̃400 patients from approximately 16 countries and 150 sites globally. Clinical trial information: NCT04712097." @default.
• W4281629140 created "2022-06-13" @default.
• W4281629140 creator A5012012199 @default.
• W4281629140 creator A5017916035 @default.
• W4281629140 creator A5023107894 @default.
• W4281629140 creator A5031678815 @default.
• W4281629140 creator A5037878906 @default.
• W4281629140 creator A5044218901 @default.
• W4281629140 creator A5045941652 @default.
• W4281629140 creator A5046386901 @default.
• W4281629140 creator A5051605599 @default.
• W4281629140 creator A5068999622 @default.
• W4281629140 creator A5078397650 @default.
• W4281629140 creator A5080620360 @default.
• W4281629140 creator A5089004534 @default.
• W4281629140 date "2022-06-01" @default.
• W4281629140 modified "2023-09-30" @default.
• W4281629140 title "CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy." @default.
• W4281629140 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps7588" @default.
• W4281629140 hasPublicationYear "2022" @default.
• W4281629140 type Work @default.
• W4281629140 citedByCount "5" @default.
• W4281629140 countsByYear W42816291402022 @default.
• W4281629140 countsByYear W42816291402023 @default.
• W4281629140 crossrefType "journal-article" @default.
• W4281629140 hasAuthorship W4281629140A5012012199 @default.
• W4281629140 hasAuthorship W4281629140A5017916035 @default.
• W4281629140 hasAuthorship W4281629140A5023107894 @default.
• W4281629140 hasAuthorship W4281629140A5031678815 @default.
• W4281629140 hasAuthorship W4281629140A5037878906 @default.
• W4281629140 hasAuthorship W4281629140A5044218901 @default.
• W4281629140 hasAuthorship W4281629140A5045941652 @default.
• W4281629140 hasAuthorship W4281629140A5046386901 @default.
• W4281629140 hasAuthorship W4281629140A5051605599 @default.
• W4281629140 hasAuthorship W4281629140A5068999622 @default.
• W4281629140 hasAuthorship W4281629140A5078397650 @default.
• W4281629140 hasAuthorship W4281629140A5080620360 @default.
• W4281629140 hasAuthorship W4281629140A5089004534 @default.
• W4281629140 hasConcept C121332964 @default.
• W4281629140 hasConcept C126322002 @default.
• W4281629140 hasConcept C142424586 @default.
• W4281629140 hasConcept C143998085 @default.
• W4281629140 hasConcept C2776063141 @default.
• W4281629140 hasConcept C2776364478 @default.
• W4281629140 hasConcept C2776694085 @default.
• W4281629140 hasConcept C2777058707 @default.
• W4281629140 hasConcept C2777063308 @default.
• W4281629140 hasConcept C2779338263 @default.
• W4281629140 hasConcept C2780653079 @default.
• W4281629140 hasConcept C31760486 @default.
• W4281629140 hasConcept C71924100 @default.
• W4281629140 hasConcept C87355193 @default.
• W4281629140 hasConcept C90924648 @default.
• W4281629140 hasConceptScore W4281629140C121332964 @default.
• W4281629140 hasConceptScore W4281629140C126322002 @default.
• W4281629140 hasConceptScore W4281629140C142424586 @default.
• W4281629140 hasConceptScore W4281629140C143998085 @default.
• W4281629140 hasConceptScore W4281629140C2776063141 @default.
• W4281629140 hasConceptScore W4281629140C2776364478 @default.
• W4281629140 hasConceptScore W4281629140C2776694085 @default.
• W4281629140 hasConceptScore W4281629140C2777058707 @default.
• W4281629140 hasConceptScore W4281629140C2777063308 @default.
• W4281629140 hasConceptScore W4281629140C2779338263 @default.
• W4281629140 hasConceptScore W4281629140C2780653079 @default.
• W4281629140 hasConceptScore W4281629140C31760486 @default.
• W4281629140 hasConceptScore W4281629140C71924100 @default.
• W4281629140 hasConceptScore W4281629140C87355193 @default.
• W4281629140 hasConceptScore W4281629140C90924648 @default.
• W4281629140 hasIssue "16_suppl" @default.
• W4281629140 hasLocation W42816291401 @default.
• W4281629140 hasOpenAccess W4281629140 @default.
• W4281629140 hasPrimaryLocation W42816291401 @default.
• W4281629140 hasRelatedWork W2727802946 @default.
• W4281629140 hasRelatedWork W2926744043 @default.
• W4281629140 hasRelatedWork W2951033984 @default.
• W4281629140 hasRelatedWork W3014926372 @default.
• W4281629140 hasRelatedWork W3168899802 @default.
• W4281629140 hasRelatedWork W3175867787 @default.
• W4281629140 hasRelatedWork W4281678979 @default.
• W4281629140 hasRelatedWork W4283328755 @default.
• W4281629140 hasRelatedWork W4296532704 @default.
• W4281629140 hasRelatedWork W4296533012 @default.
• W4281629140 hasVolume "40" @default.
• W4281629140 isParatext "false" @default.
• W4281629140 isRetracted "false" @default.
• W4281629140 workType "article" @default.